A fetal tracing deteriorates during an oxytocin infusion.
The infusion continues.
Contractions become more frequent.
Someone notices.
Someone else assumes the obstetrician has already been called.
The dose is eventually reduced.
Then comes prolonged bradycardia, an emergency cesarean, and an injured newborn.
Years later, the malpractice case is described in five words:
“They gave too much Pitocin.”
But that description may miss the more important problem.
The drug did not fail.
The system around the drug may have failed.
Oxytocin Is Not an Ordinary Medication
Oxytocin is one of the most familiar medications in obstetrics. Familiarity can make us forget how consequential it is.
The Institute for Safe Medication Practices includes intravenous oxytocin on its list of high-alert medications in acute care settings. “High alert” does not mean the drug should rarely be used. It means that errors involving it can cause substantial harm and therefore deserve safeguards.
Oxytocin changes uterine activity.
More contractions are not always better contractions.
Excessive uterine activity can reduce the interval during which placental blood flow recovers between contractions. In a fetus with limited reserve, that may matter greatly.
A recent analysis embedded within the randomized STOPOXY trial found that stopping oxytocin in active labor was followed by fewer contractions and fewer fetal heart rate decelerations in the following hour. Importantly, this physiologic finding does not prove that discontinuing oxytocin is always superior or that continuation represents negligence. It demonstrates something simpler: oxytocin exposure can materially affect uterine activity and fetal heart rate patterns.
That is why its administration requires active management.
